Literature DB >> 31620202

The combined use of EphA2/MMP-2 expression and MRI findings contributes to the determination of cerebral glioma grade.

Fangfang Suo1, Binfeng Zhong2, Fangfang Lu1, Zhihui Dong1.   

Abstract

Glioma is the most aggressive brain tumor and is associated with a high mortality rate. The aim of the present study was to explore the association between matrix metalloproteinase 2 (MMP-2) and ephrin type-A receptor 2 (EphA2) expression in glioma cells, and to investigate the contribution of magnetic resonance imaging (MRI) in glioma classification. A total of 43 patients with pathologically confirmed glioma were divided into two groups as follows: Low-grade (grades I and II; n=21) and high-grade (grades IV and IV; n=22). Subsequently, immunohistochemistry staining was performed to detect the expression levels of MMP-2 and EphA2 in the low- and high-grade groups. MRI routine and enhanced scans were used to measure the peritumoral edema index (EI), tumor enhancement percentage (EP) and maximum tumor diameter. The results demonstrated that the proportion of MMP-2-positive patients in the high-grade group was 86.36% (19/22), which was significantly higher than that of the low-grade group (57.14%; 12/21) (P<0.05). Furthermore, the proportion of EphA2-positive patients in the high-grade group was 90.91% (20/22), significantly higher than that in the low-grade group (4.76%; 1/21) (P<0.01). In addition, the MRI results indicated that the EI, EP and maximum tumor diameter were significantly higher in the high-grade group compared with the low-grade group (P<0.01, P<0.01 and P<0.05, respectively). Finally, the expression levels of MMP-2 and EphA2 were significantly associated with the EI, EP and maximum tumor diameter (all P<0.05). In conclusion, the expression levels of MMP-2 and EphA2 were positively correlated with glioma invasion. The correlation between these expression levels and MRI assessment of the EI, EP and maximum tumor diameter indicated that the combination of these two methods may be used for the evaluation of the tumor grade and for further clinical treatment applications.
Copyright © 2019, Spandidos Publications.

Entities:  

Keywords:  ephrin type-A receptor 2; glioma; magnetic resonance imaging; matrix metalloproteinase 2

Year:  2019        PMID: 31620202      PMCID: PMC6788174          DOI: 10.3892/ol.2019.10912

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  51 in total

1.  The use of the Karnofsky Performance Scale in determining outcomes and risk in geriatric outpatients.

Authors:  V Crooks; S Waller; T Smith; T J Hahn
Journal:  J Gerontol       Date:  1991-07

2.  Migfilin promotes migration and invasion in glioma by driving EGFR and MMP-2 signalings: A positive feedback loop regulation.

Authors:  Yunwei Ou; Qingnan Wu; Chuanyue Wu; Xuefeng Liu; Yongmei Song; Qimin Zhan
Journal:  J Genet Genomics       Date:  2017-10-16       Impact factor: 4.275

Review 3.  Matrix metalloproteinases and cancer - roles in threat and therapy.

Authors:  Lalita Yadav; Naveen Puri; Varun Rastogi; Pranali Satpute; Riyaz Ahmad; Geetpriya Kaur
Journal:  Asian Pac J Cancer Prev       Date:  2014

4.  Gd-EOB-DTPA-enhanced magnetic resonance imaging for bile duct intraductal papillary mucinous neoplasms.

Authors:  Shi-Hong Ying; Xiao-Dong Teng; Zhao-Ming Wang; Qi-Dong Wang; Yi-Lei Zhao; Feng Chen; Wen-Bo Xiao
Journal:  World J Gastroenterol       Date:  2015-07-07       Impact factor: 5.742

5.  Reduced angiogenesis and tumor progression in gelatinase A-deficient mice.

Authors:  T Itoh; M Tanioka; H Yoshida; T Yoshioka; H Nishimoto; S Itohara
Journal:  Cancer Res       Date:  1998-03-01       Impact factor: 12.701

Review 6.  EphA2 receptor tyrosine kinase as a promising target for cancer therapeutics.

Authors:  Reneé C Ireton; Jin Chen
Journal:  Curr Cancer Drug Targets       Date:  2005-05       Impact factor: 3.428

7.  Relationship between survival and edema in malignant gliomas: role of vascular endothelial growth factor and neuronal pentraxin 2.

Authors:  Marc R J Carlson; Whitney B Pope; Steve Horvath; Jerome G Braunstein; Phioanh Nghiemphu; Cho-Lea Tso; Ingo Mellinghoff; Albert Lai; Linda M Liau; Paul S Mischel; Jun Dong; Stanley F Nelson; Timothy F Cloughesy
Journal:  Clin Cancer Res       Date:  2007-05-01       Impact factor: 12.531

Review 8.  Gadolinium-based contrast agents for magnetic resonance cancer imaging.

Authors:  Zhuxian Zhou; Zheng-Rong Lu
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2012-10-09

9.  EphA2 promotes infiltrative invasion of glioma stem cells in vivo through cross-talk with Akt and regulates stem cell properties.

Authors:  H Miao; N W Gale; H Guo; J Qian; A Petty; J Kaspar; A J Murphy; D M Valenzuela; G Yancopoulos; D Hambardzumyan; J D Lathia; J N Rich; J Lee; B Wang
Journal:  Oncogene       Date:  2014-02-03       Impact factor: 9.867

Review 10.  Perfusion magnetic resonance imaging: a comprehensive update on principles and techniques.

Authors:  Geon-Ho Jahng; Ka-Loh Li; Leif Ostergaard; Fernando Calamante
Journal:  Korean J Radiol       Date:  2014-09-12       Impact factor: 3.500

View more
  3 in total

1.  EPHA2, EPHA4, and EPHA6 Expression in Uveal Melanomas: Searching for the Culprits of Neoplasia.

Authors:  Alexandros Pergaris; Eugene Danas; Pawel Gajdzis; Georgia Levidou; Malgorzata Gajdzis; Nathalie Cassoux; Sophie Gardrat; Piotr Donizy; Penelope Korkolopoulou; Nikolaos Kavantzas; Jerzy Klijanienko; Stamatios Theocharis
Journal:  Diagnostics (Basel)       Date:  2022-04-19

Review 2.  EphrinB2-EphB4 Signaling in Neurooncological Disease.

Authors:  Andras Piffko; Christian Uhl; Peter Vajkoczy; Marcus Czabanka; Thomas Broggini
Journal:  Int J Mol Sci       Date:  2022-01-31       Impact factor: 5.923

3.  Radiomics-based MRI for predicting Erythropoietin-producing hepatocellular receptor A2 expression and tumor grade in brain diffuse gliomas.

Authors:  Xiaoxue Liu; Jianrui Li; Xiang Liao; Zhongqiang Luo; Qiang Xu; Hao Pan; Qing Zhou; Yan Tao; Feng Shi; Guangming Lu; Zhiqiang Zhang
Journal:  Neuroradiology       Date:  2021-08-09       Impact factor: 2.804

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.